Current Report Filing (8-k)
February 17 2017 - 6:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 17, 2017
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
Massachusetts
|
|
0-17999
|
|
04-2726691
|
(State or other
jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
830 Winter Street, Waltham, MA 02451
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code:
(781) 895-0600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION
On February 17, 2017, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the companys financial results for the quarter and six months ended December 31, 2016. The press release announcing financial results for the quarter and six months ended December 31, 2016 is included as Exhibit 99.1 and incorporated herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d): The following exhibit is being furnished herewith:
Exhibit No.
|
|
Exhibit
|
|
|
|
99.1
|
|
Press Release of ImmunoGen, Inc. dated February 17, 2017
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ImmunoGen, Inc.
|
|
(Registrant)
|
|
|
Date: February 17, 2017
|
/s/ David B. Johnston
|
|
|
|
David B. Johnston
|
|
Executive Vice President and Chief Financial Officer
|
3
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024